Veracyte, Inc. · NASDAQ:VCYT
Veracyte — Merger or Acquisition (February 2021)
17 slides from Veracyte's merger presentation, Feb 3, 2021
Slide 1: Decipher Biosciences Acquisition Further Solidifies Global Leadership in Cancer Diagnostics and Accelerates Growth
Decipher Biosciences Acquisition Further Solidifies Global Leadership in Cancer Diagnostics and Accelerates Growth ANSWERS February 3, 2021 ® Veracyte, Inc. All rights reserved. Filed by Veracyte, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Companies: Veracyte, Inc
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the anticipated acquisition of Decipher Biosciences; statements regar
Slide 3: Our vision is to improve outcomes for patients all over the world
Our vision is to improve outcomes for patients all over the world at every step of their journey. ® Veracyte, Inc. All rights reserved. February 3, 2021
Slide 4: Genomic tests targeting multiple diseases across care continuum
Genomic tests targeting multiple diseases across care continuum Veracyte today February 3, 2021 ® Veracyte, Inc. All rights reserved. 1Investigational product 2Percepta Genomic Atlas is US only Basel Nasal Swab Test Lum A/B Pre-Cancer Detection Treatment LymphMark™ Nasal Swab Test Early Detection Di
Slide 5: A global platform for international expansion
nCounter Nasal Swab LymphMark™ CLIA LAB Nasal Swab LymphMark™ LymphMark™ A global platform for international expansion Veracyte today Transplant ® Veracyte, Inc. All rights reserved. February 3, 2021
Slide 6: Combination creates comprehensive portfolio of novel genomic diagnostic tests
February 3, 2021 ® Veracyte, Inc. All rights reserved. Drives market, menu and global expansion Accelerates growth Combination creates comprehensive portfolio of novel genomic diagnostic tests addressing 7 of the top 10 cancers
Slide 7: Decipher Biosciences overview: a market leader in urologic cancer genomic diagnostics
A market leader in urologic cancer genomic diagnostics Decipher Biosciences overview Commercial-stage precision oncology company focused on $2B urologic cancer market Approximately 100 full-time employees, large CLIA- and CAP-certified lab in San Diego Unique product portfolio spanning the entire lo
Slide 8: Significant commercial traction in large markets
Significant commercial traction in large markets Decipher Biosciences urologic cancer tests Product Portfolio Product Indications 2020 U.S. Estimated Incidence1 Clinical Evidence Commercialization Analytic Validation Clinical Validation Clinical Utility Medicare Coverage NCCN Guideline Inclusion Com
Slide 9: Decipher Biosciences in prostate cancer enables personalized treatment
Enables physicians to personalize treatment across localized disease Decipher Biosciences in prostate cancer February 3 , 2021 ® Veracyte, Inc. All rights reserved. Initial Management Definitive Therapy After Surgery At BCR Active Surveillance or Treat? Treatment Intensity? Early or Salvage Radiatio
Slide 10: Decipher GRID: comprehensive urologic cancer biorepository
Comprehensive urologic cancer biorepository to drive further value Decipher GRID >300 Clinically Validated Prognostic/Predictive Signatures supported by >200 publications Genomics & Proprietary Signatures >15,000 Patients from Clinical Trials Clinical Trials Community Patients from >3,200 U.S. Physi
Slide 11: Market and menu expansion accelerates growth
Market and menu expansion accelerates growth ~680,000 patients/year ~1,100,000 patients/year VERACYTE Addressing 4 of top 10 cancers VERACYTE + Decipher Biosciences Addressing 7 of top 10 cancers ~60% increase Top cancers in US by incidence $2B+ TAM in US alone ® Veracyte, Inc. All rights reserved.
Slide 12: Further solidifies our global leadership
LymphMark™ CLIA LAB Nasal Swab LymphMark™ Further solidifies our global leadership February 3, 2021 ® Veracyte, Inc. All rights reserved. ~$50+ BILLION LONG-TERM GLOBAL TAM CLIA LAB Decipher: Prostate Decipher: Bladder Decipher: Kidney nCounter Transplant Decipher: Prostate Decipher: Bladder Deciphe
Slide 13: Accelerates our strategic growth pathway
Accelerates our strategic growth pathway February 3, 2021 Whole transcriptome sequencing and machine learning Strategic partnerships Menu expansion Global diagnostic testing and platform leader Atlas Xpression Atlas Nasal Swab IPF Prognostic LymphMark™ Scientific Excellence Channel Expansion Menu Ex
Slide 14: Total consideration of $600 million
Total consideration of $600 million Transaction terms Total Consideration Cash + Equity $600 million $250 million Up to $350 million Veracyte has the option at its sole discretion to substitute cash in lieu of shares in any amount up to the entire stock consideration1. For purposes of any substituti
Slide 15: Accelerating Revenue Growth and Pathway to Profitability
+37% 139% YoY +106% Accelerating Revenue Growth and Pathway to Profitability Illustrative Pro Forma Financials ($ in millions) Decipher Biosciences Historical Standalone Revenue2020 Pro Forma[2021 Guidance] Veracyte Q4 2020 Annualized +30% Revenue Growth Revenue Growth +31% (2)% YoY +16% Source: * F
Slide 16: Experienced team with track record of success
Experienced team with track record of success Bonnie Anderson Chairman and Chief Executive Officer Giulia C. Kennedy, Ph.D. Chief Scientific Officer and Chief Medical Officer Keith Kennedy Chief Financial Officer and Chief Operating Officer John Hanna General Manager, Endocrinology, Breast Cancer an
Slide 17: Veracyte
Wvera cyte.